Hans-Georg Kopp Dept. of Hematology, Oncology and Immunology University of Tübingen Biography Publications Institution JoVE Articles Hans-Georg Kopp has not added a biography. If you are Hans-Georg Kopp and would like to personalize this page please email our Author Liaison for assistance. Publications Long-term Remission of Refractory Rosai-Dorfman Disease After Salvage Therapy with Clofarabine in an Adult Patient Annals of Hematology. Jul, 2018 | Pubmed ID: 29980874 Impact of Surgery in Patients with Metastatic Soft Tissue Sarcoma: A Monocentric Retrospective Analysis Journal of Surgical Oncology. Jul, 2018 | Pubmed ID: 29953623 Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation Cancer Research. Aug, 2018 | Pubmed ID: 29789417 NFAT2 is a Critical Regulator of the Anergic Phenotype in Chronic Lymphocytic Leukaemia Nature Communications. 10, 2017 | Pubmed ID: 28970470 Enhanced Eryptosis Contributes to Anemia in Lung Cancer Patients Oncotarget. Mar, 2016 | Pubmed ID: 26872376 Management of Disseminated Intravascular Coagulopathy with Direct Factor Xa Inhibitor Rivaroxaban in Klippel-Trénaunay Syndrome Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis. Oct, 2013 | Pubmed ID: 24030117 Long-term Results After Transplantation of CD34+ Selected (CellPro) Versus Unselected Peripheral Blood Progenitor Cells (PBPC) from Related Allogeneic Donors Journal of Cancer Research and Clinical Oncology. Dec, 2010 | Pubmed ID: 20217128 Wnt1 Overexpression Leads to Enforced Cardiomyogenesis and Inhibition of Hematopoiesis in Murine Embryonic Stem Cells Stem Cells and Development. May, 2010 | Pubmed ID: 19422288 Myeloma Cell Contamination of Peripheral Blood Stem-cell Grafts Can Predict the Outcome in Multiple Myeloma Patients After High-dose Chemotherapy and Autologous Stem-cell Transplantation Journal of Cancer Research and Clinical Oncology. Apr, 2005 | Pubmed ID: 15616828 الإنزيم إيمونوبريسيبيتيشن الكروماتين لتحديد الجينات المستهدفة NFAT2 الرواية في سرطان الدم الليمفاوي المزمن Alexander R. Fuchs1, Melanie Märklin1, Jonas S. Heitmann1, Stefan Futterknecht1, Michael Haap2, Stefan Wirths1, Hans-Georg Kopp1, Clemens Hinterleitner1, Daniela Dörfel1, Martin R. Müller1 1Dept. of Hematology, Oncology and Immunology, University of Tübingen, 2Dept. of Endocrinology, Diabetology, Clinical Pathology and Metabolism, University of Tübingen JoVE 58270 Cancer Research
الإنزيم إيمونوبريسيبيتيشن الكروماتين لتحديد الجينات المستهدفة NFAT2 الرواية في سرطان الدم الليمفاوي المزمن Alexander R. Fuchs1, Melanie Märklin1, Jonas S. Heitmann1, Stefan Futterknecht1, Michael Haap2, Stefan Wirths1, Hans-Georg Kopp1, Clemens Hinterleitner1, Daniela Dörfel1, Martin R. Müller1 1Dept. of Hematology, Oncology and Immunology, University of Tübingen, 2Dept. of Endocrinology, Diabetology, Clinical Pathology and Metabolism, University of Tübingen JoVE 58270 Cancer Research